Contemporary HIV-1 consensus Env with AI-assisted redesigned hypervariable loops promote antibody binding

Nat Commun. 2024 May 9;15(1):3924. doi: 10.1038/s41467-024-48139-x.

Abstract

An effective HIV-1 vaccine must elicit broadly neutralizing antibodies (bnAbs) against highly diverse Envelope glycoproteins (Env). Since Env with the longest hypervariable (HV) loops is more resistant to the cognate bnAbs than Env with shorter HV loops, we redesigned hypervariable loops for updated Env consensus sequences of subtypes B and C and CRF01_AE. Using modeling with AlphaFold2, we reduced the length of V1, V2, and V5 HV loops while maintaining the integrity of the Env structure and glycan shield, and modified the V4 HV loop. Spacers are designed to limit strain-specific targeting. All updated Env are infectious as pseudoviruses. Preliminary structural characterization suggests that the modified HV loops have a limited impact on Env's conformation. Binding assays show improved binding to modified subtype B and CRF01_AE Env but not to subtype C Env. Neutralization assays show increases in sensitivity to bnAbs, although not always consistently across clades. Strikingly, the HV loop modification renders the resistant CRF01_AE Env sensitive to 10-1074 despite the absence of a glycan at N332.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • AIDS Vaccines / immunology
  • Antibodies, Neutralizing* / immunology
  • Consensus Sequence
  • Epitopes / immunology
  • HEK293 Cells
  • HIV Antibodies* / immunology
  • HIV Infections / immunology
  • HIV Infections / virology
  • HIV-1* / immunology
  • Humans
  • Neutralization Tests
  • Protein Binding
  • env Gene Products, Human Immunodeficiency Virus* / chemistry
  • env Gene Products, Human Immunodeficiency Virus* / immunology
  • env Gene Products, Human Immunodeficiency Virus* / metabolism

Substances

  • env Gene Products, Human Immunodeficiency Virus
  • HIV Antibodies
  • Antibodies, Neutralizing
  • AIDS Vaccines
  • Epitopes